Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AGRX > SEC Filings for AGRX > Form 8-K on 13-Jul-2016All Recent SEC Filings

Show all filings for AGILE THERAPEUTICS INC

Form 8-K for AGILE THERAPEUTICS INC


13-Jul-2016

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.

On July 12, 2016, Agile Therapeutics, Inc. ("Agile") issued a press release announcing that preparations are underway for an initial Phase 2 clinical trial of a novel contraceptive regimen, which will begin the development of its pipeline beyond its current lead product candidate, Twirlaź, a once weekly contraceptive patch currently in Phase 3 development. The planned Phase 2 clinical trial will examine the use of Twirla in an innovative regimen designed to allow women to experience shorter, lighter periods, using a smaller lower dose combination ethinyl estradiol/levonorgestrel patch ("SmP"). Agile has started preparations for the trial and expects to initiate dosing in the first quarter of 2017. Agile also announced that it has plans to develop an extended cycle regimen for Twirla (AG200-ER) that may also utilize the SmP with the goal of allowing women to have fewer periods each year.

On July 12, 2016, Agile also updated its corporate presentation that it intends to use in connection with presentations at conferences and meetings with investors. The updates include the information on its pipeline announced in the press release referenced above and the appointment of a new chief commercial officer, which was previously announced.

Copies of Agile's press release and presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and are hereby incorporated by reference herein.



Item 9.01. Financial Statements and Exhibits.

(d)                 Exhibits.



Exhibit
Number                            Description


99.1 Agile Therapeutics, Inc. Press Release dated July 12, 2016.
99.2 Agile Therapeutics, Inc. Presentation.


  Add AGRX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AGRX - All Recent SEC Filings
Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.